Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction

Haematologica. 2022 Aug 1;107(8):2004-2007. doi: 10.3324/haematol.2022.280843.

Authors

Deepak B Vangala¹, Verena Nilius-Eliliwi¹, Thomas Mika¹, Thilo Gambichler², Rene Stranzenbach², Roland Schroers³

Affiliations

¹ Department of Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum.
² Skin Cancer Center, Department of Dermatology, St. Joseph Hospital, Ruhr-University Bochum.
³ Department of Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum. Roland.Schroers@rub.de.

No abstract available

MeSH terms

Dendritic Cells
Hematologic Neoplasms* / therapy
Humans
Interleukin-3 Receptor alpha Subunit
Myeloproliferative Disorders*
Recombinant Fusion Proteins
Skin Neoplasms*

Substances

Interleukin-3 Receptor alpha Subunit
Recombinant Fusion Proteins
tagraxofusp